Welcome to ActionLyme - the Lyme Cryme Whistleblower's Website

IDSA's Secrets:

Bioweapon Attributes Dickson FDA Yale USDOJ RICO

Pam3Cys - AIDS

PubMed: TLR2

"New World Disorder"
IDSA's Persistence "Cryme Disease" book Klempner's Fraud RICO Patents Osp-A/Viral Synergy Grants Search "TLR2" Kissinger NWO Beast
Relapsing Fever Dearborn Quotes Plum Island Corixa-Imugen RICO "LYMErix ▲ Disease" Myco & Erythrocytes Rx Brain Damage
Steere Falsifies Test Dearborn Booklet Russians & NYMC CDCs Patents w/SKB Pam3Cys_ImmuSupp GarthNicolson-GWI Rockefeller/Psychiatry
IDSA's Imitators Schoen-LYMErix IDSA: "Cyst Viable" DARPA Boots CDC Confronting NIH CT Med Board Hell/NDEs
IDSA's ShellGame Weinstein's Frauds LYMErix ►Imitators Auwaerter EBV NIH Disinfo Foreign CPS' Sexual Assaults
IDSA's Biomarkers Yale's Valid Test UConn's KidTuskegee Plum Stupid Vaccines' Brain Damage Fraud With Intent   CPS' Entrapment
IDSA's Stupid Rx
 
Not used ▲to assess LYMErix, other patent. Yale's Congen Lyme
 
IDSA ▲ self-indicts
 

 
Update on Sex Abuse
 

 

05/21/2013 09:15:51

Index/Home

Cryme Trainer (moved)


Non-HLA-linked Diseases
Hurricane Sandy and Mold-Related illnesses (like LYMErix and Lyme Disease, and CFIDS/FM).


=======

References for psychotropics-induced brain damage


Older data on the incurability of Relapsing Fever

1986, McSweegan trashes Navy for $$$ for ALDF.com

1988, Dattwyler & about immune-suppressing, seronegative Lyme

1990, CDC: "Diagnose Lyme as if it was Relapsing Fever."

Allen Steere  "NeuroLyme won't test positive," 1990.

1992, CDC officer Allen Steere falsifies testing in Europe

1992, CDC patents with SmithKline show 2 kinds of Lyme

Compare the 2 kinds of Lyme in the RICO complaint

1994, CDC's Dearborn Booklet .pdf

CDC's invitation to participate in Dearborn .pdf

Igenex, Harris, Dearborn .pdf

Evidence  Lyme criminals knew LYMErix produced the same "multisystem disease" as "Chronic Lyme"

LYMErix Damage Coverup (short)
 

120302 NIH Treatments
 

1998, CIA Oilmen & Israelis plan to overthrow Saddam for the oil.

Bush/Gore  Oil/War-(Oct,2000)  

Bush's own explainer (Oct 2000) re: Iraq Oil



Steere's "Seronegative Lyme" Hysteria about OspA-induced Antibody Inhibition
Read about it also in the 1998 FDA LYMErix meeting transcript:
http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3422t1.rtf

1990
; Steere using Dattwyler and Volkman's Seronegative Lyme Assay (developed because Dattwyler knew fungal antigens produced immunosuppression) to evaluate "Chronic Neurologic Lyme" cases:


http://www.nejm.org/doi/pdf/10.1056/NEJM199011223232102


See Also, CRYMEDISEASE_CHP3_B.htm  where we show Steere in 1991 actually used this seronegative Lyme assay on his own lab
workers, 101016.htm (
http://www.ncbi.nlm.nih.gov/pubmed/1883122)  where we see Steere knowingly falsely advising the Academy
of Insurance Medicine a year later (1992), and the Plum Island Chapter of Cryme Disease where Justin Radolf demonstrates in 2001
that OspA vaccination (or autovaccination via blebbing), results in inhibition of antibody production via downregulation of HLA.

N  1988 Dec 1;319(22):1441-6.

Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi.

Source

Department of Medicine, State University of New York, School of Medicine, Stony Brook 11794-8161.

Abstract

The diagnosis of Lyme disease often depends on the measurement of serum antibodies to Borrelia burgdorferi, the spirochete that causes this disorder. Although prompt treatment with antibiotics may abrogate the antibody response to the infection, symptoms persist in some patients. We studied 17 patients who had presented with acute Lyme disease and received prompt treatment with oral antibiotics, but in whom chronic Lyme disease subsequently developed. Although these patients had clinically active disease, none had diagnostic levels of antibodies to B. burgdorferi on either a standard enzyme-linked immunosorbent assay or immunofluorescence assay. On Western blot analysis, the level of immunoglobulin reactivity against B. burgdorferi in serum from these patients was no greater than that in serum from normal controls. The patients had a vigorous T-cell proliferative response to whole B. burgdorferi, with a mean ( +/- SEM) stimulation index of 17.8 +/- 3.3, similar to that (15.8 +/- 3.2) in 18 patients with chronic Lyme disease who had detectable antibodies. The T-cell response of both groups was greater than that of a control group of healthy subjects (3.1 +/- 0.5; P less than 0.001). We conclude that the presence of chronic Lyme disease cannot be excluded by the absence of antibodies against B. burgdorferi and that a specific T-cell blastogenic response to B. burgdorferi is evidence of infection in seronegative patients with clinical indications of chronic Lyme disease.

Comment in

http://www.ncbi.nlm.nih.gov/pubmed/3054554